Randomized, double-blind, placebo-controlled study of F17464, a preferential D(3) antagonist, in the treatment of acute exacerbation of schizophrenia

Por Bitter, Istvan, Lieberman, Jeffrey A., Gaudoux, Florence, Sokoloff, Pierre, Groc, Mélanie, Chavda, Rajeev, Delsol, Cécile, Barthe, Laurence, Brunner, Valérie, Fabre, Carine, Fagard, Marine, Montagne, Agnès, Tonner, Françoise
Publicado no Neuropsychopharmacology (2019)